Aller au contenu principal
Fermer
  2. Aide
  2. Aide

Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Responses at 24 Months with Individualized Cancer Vaccine TG4050
information fournie par Boursorama CP 01/06/2025 à 19:15

All patients in the treatment arm remain disease-free after a minimum of 2-year follow-up in the randomized Phase I trial in resected HPV-negative locally advanced head and neck cancer – Demonstrating clinical proof of principle for TG4050
Single agent TG4050 induced long-lasting neoantigen-specific CD8+ T cell responses
Treatment was well-tolerated with no unexpected safety signals
Data presented during rapid oral session at ASCO 2025


Conference call scheduled on Friday June 6, 2025 at 3:00 p.m. CET (in English). See details below



Strasbourg, France & Tokyo, Japan, June 1st, 2025, 7:15 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation (NEC; TSE: 6701), a leader in IT, network and AI technologies, have presented new positive data on TG4050 in a rapid oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting.

.../...

Valeurs associées

TRANSGENE
0,7700 EUR Euronext Paris -0,65%

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

valeur

dernier

var.
CAC 40
8 506,27 +0,31%
SOITEC
103,3 -12,75%
2CRSI
37,74 -3,82%
Pétrole Brent
72,71 +0,97%
GENFIT
13,2 -1,49%
Chargement...

Pages les plus populaires

L'offre BoursoBank